AstraZeneca
AZN
949 hedge funds and large institutions have $29.4B invested in AstraZeneca in 2021 Q4 according to their latest regulatory filings, with 148 funds opening new positions, 270 increasing their positions, 325 reducing their positions, and 88 closing their positions.
68% more first-time investments, than exits
New positions opened: 148 | Existing positions closed: 88
43% more call options, than puts
Call options by funds: $729M | Put options by funds: $511M
5% more funds holding
Funds holding: 908 → 949 (+41)
0.41% less ownership
Funds ownership: 16.7% → 16.29% (-0.41%)
5% less capital invested
Capital invested by funds: $31.1B → $29.4B (-$1.7B)
17% less repeat investments, than reductions
Existing positions increased: 270 | Existing positions reduced: 325
24% less funds holding in top 10
Funds holding in top 10: 17 → 13 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$442M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
+$151M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$108M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$92.5M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$85.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$355M |
| 2 |
Goldman Sachs
New York
|
-$308M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
-$149M |
| 4 |
BlackRock
New York
|
-$129M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$121M |
AZN Hedge Fund Activity: Q4 2021 in Review
949 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q4 2021, worth a combined $29.4B — down 5.5% from $31.1B a quarter earlier.
Buyers outnumbered sellers: 148 funds opened new AZN positions and 88 closed out — a net gain of 60 holders — while 270 added to existing stakes and 325 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $442M. The largest seller was Wellington Management Group, cutting an estimated $355M.
- 949 institutional investors held AstraZeneca (AZN) as of Q4 2021, up from 908 in Q3 2021.
- Funds reported $29.4B of AstraZeneca stock for Q4 2021, down 5.5% quarter-over-quarter.
- 148 funds opened new AstraZeneca positions in Q4 2021 and 88 closed out, a net change of +60 holders.
- The largest AstraZeneca buyer in Q4 2021 was T. Rowe Price Associates, an estimated $442M added.
- The largest AstraZeneca seller in Q4 2021 was Wellington Management Group, an estimated $355M sold.
Based on aggregated 13F filings for Q4 2021.